Efficacy and safety of SOXIRI <i>versus</i> mFOLFIRINOX in advanced pancreatic cancer.

"The authors declare that there is no conflict of interest."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was supported in part by grants from the Natural Science Foundation of Guangdong Province (grant number 2021A1515012368 and 2023A1515010783)."

"This study retrospectively analysed electronic clinical medical records of patients with locally advanced or metastatic pancreatic cancer who received first-line SOXIRI or mFOLFIRINOX at Sun Yat-sen University Cancer Center from July 2012 to June 2021. For locally advanced pancreatic cancer, we first diagnosed according to the criteria of NCCN guidelines. Only when there was a diagnostic dispute did we organize a multidisciplinary team to discuss it and record the final diagnosis in the electronic medical record. Approximately half of the patients in this study had participated in clinical studies led by Sun Yat-sen University Cancer Center. Of these, 61% of the patients in the SOXIRI regimen had participated in a phase II single-centre clinical trial of SOXIRI, whereas 40% of the patients in the mFOLFIRINOX regimen had participated in a phase II multicentre clinical trial of mFOLFIRINOX. Both clinical trials were registered in ClinicalTrials.gov with the numbers ChiCTR1800018233 and NCT02028806. This indicates that the source of our clinical data is reliable and of high quality. The follow-up period was up to 20 February 2022."